Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
- Publication date
- 1 September 2019
- Publisher
- Providence St. Joseph Health Digital Commons